BioLight

Executive Summary

BioLight Life Sciences Ltd. is an Israeli public holding company exclusively focused on ophthalmology, investing in a portfolio of companies developing advanced medical devices, diagnostics, digital health, and nanostructure-based drug delivery solutions for eye diseases. Founded in 2003 and headquartered in Ramat Gan, Israel, BioLight targets high-need areas such as dry eye, glaucoma, uveitis, and retinal disorders. With an estimated valuation of ~$9.4 million and total raised of $5.5 million, the company operates as a platform, managing a diversified pipeline of early-stage ophthalmic innovations. Its business model leverages strategic investments to de-risk development while capturing upside from multiple product candidates. As a public entity, BioLight offers investors exposure to a broad ophthalmology portfolio without the full risk of any single asset.

Upcoming Catalysts (preview)

• Q4 2026Clinical Data Readout for Dry Eye Drug Delivery Platform40% success
• Q2 2027Partnership or Licensing Deal for Glaucoma Device30% success
• TBDRegulatory Milestone for Retinal Implant Candidate20% success